LUCD: the cash flow

MyFinsight

For the year ending 2025-12-31, LUCD had $12,347K increase in cash & cash equivalents over the period. -$46,682K in free cash flow.

Cash Flow	2025-12-31
Net loss	-58,010
Depreciation and amortization expense	872
Stock-based compensation-Lucid Diagnostics2018Equity Plan	4,387
Stock-based compensation-Pavmed2014Equity Plan	104
Change in fair value - senior secured convertible note	-7,656
Debt extinguishment loss - senior secured convertible note	0
Amortization of common stock payment for vendor service agreement	234
Equity issuance cost extinguishment	-1,078
Accounts receivable	601
Prepaid expenses and other current assets	1,841
Accounts payable	-270
Accrued expenses and other current liabilities	-110
Due to pavmed inc. - operating expenses, employee related costs, msa fee-Pavmed	16
Net cash flows used in operating activities	-46,485
Purchase of equipment	197
Purchase of intellectual property from pavmed inc	0
Net cash flows used in investing activities	-197
Proceeds issue of preferred stock	0
Proceeds issue of common stock-Registered Direct Offering	14,935
Proceeds issue of common stock-Confidentially Marketed Public Offering	43,171
Proceeds issue of senior secured convertible notes	360
Payment repayment of senior secured convertible note	0
Proceeds issue of common stock-Atthemarket Offering	274
Proceeds exercise of stock options	17
Proceeds issue common stock employee stock purchase plan	272
Net cash flows provided by financing activities	59,029
Net increase (decrease) in cash	12,347
Cash, beginning of period	22,358
Cash, end of period	34,705

Unit: Thousand (K) dollars (except for numbers of shares and EPS).